What are examples of triple therapy for COPD (Chronic Obstructive Pulmonary Disease) patients with a history of exacerbations and severe symptoms, according to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) COPD guidelines of 2025?

Triple Therapy for COPD: Specific Examples Based on GOLD 2025 Guidelines

For COPD patients with high exacerbation risk (≥2 moderate or ≥1 severe exacerbation in the past year), moderate-to-high symptom burden (CAT ≥10 or mMRC ≥2), and impaired lung function (FEV1 <80% predicted), triple therapy combining a LAMA/LABA/ICS in a single inhaler is the recommended initial maintenance therapy. 1, 2

Specific Triple Therapy Combinations

The following are evidence-based triple therapy regimens delivered as single-inhaler triple therapy (SITT):

Available Fixed-Dose Triple Combinations

• Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 mcg once daily - This combination demonstrated a 25% reduction in annual moderate/severe exacerbations compared to LAMA/LABA dual therapy (0.91 vs 1.21 exacerbations/year) and a 15% reduction compared to ICS/LABA therapy (0.91 vs 1.07 exacerbations/year) in the IMPACT trial 1, 3

• Budesonide/glycopyrronium/formoterol fumarate - The ETHOS trial showed that budesonide 320 mcg triple therapy reduced the annual rate of moderate or severe exacerbations by 24% compared to LAMA/LABA dual therapy, with a demonstrated mortality benefit at this moderate ICS dose 1, 2

• Beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) 100/6/12.5 mcg per puff as an extrafine hydrofluoroalkane pressurized metered dose inhaler - This combination showed superiority over fixed ICS/LABA therapy and tiotropium monotherapy for lung function and exacerbation prevention 4, 5

Patient Selection Algorithm for Triple Therapy

Step 1: Assess Exacerbation Risk 1, 2

• High risk = ≥2 moderate exacerbations (requiring antibiotics/oral corticosteroids) OR ≥1 severe exacerbation (requiring hospitalization/ED visit) in past 12 months
• Low risk = ≤1 moderate exacerbation without hospitalization in past 12 months

Step 2: Assess Symptom Burden 1, 2

• Moderate-to-high symptoms = CAT score ≥10 OR mMRC score ≥2
• Low symptoms = CAT score <10 AND mMRC score 1

Step 3: Assess Lung Function 1, 2

• Impaired = FEV1 <80% predicted
• Preserved = FEV1 ≥80% predicted

Step 4: Apply Treatment Decision 1, 2

• High exacerbation risk + moderate-to-high symptoms + FEV1 <80% = Start LAMA/LABA/ICS triple therapy immediately
• Low exacerbation risk + moderate-to-high symptoms + FEV1 <80% = Start LAMA/LABA dual therapy
• Low exacerbation risk + low symptoms + FEV1 ≥80% = Start single LAMA or LABA

Mortality Benefit of Triple Therapy

Triple therapy LAMA/LABA/ICS demonstrates moderate certainty evidence for mortality reduction compared to LAMA/LABA dual therapy, making it the preferred treatment for high-risk patients. 1, 2 This mortality benefit was observed with moderate ICS doses (budesonide 320 mcg), indicating that higher ICS doses are not necessary for optimal outcomes 2

Biomarker-Guided Therapy

• Patients with blood eosinophils ≥300 cells/μL derive particular benefit from ICS-containing triple therapy 2, 6
• ICS should not be withdrawn from triple therapy in patients with eosinophils ≥300 cells/μL due to increased risk of moderate-to-severe exacerbations 2, 6
• For patients with blood eosinophils ≥100 cells/μL, baseline FEV1 ≤42%, and CAT score ≥18, triple therapy should be considered as first-line treatment 7

Single-Inhaler vs Multiple-Inhaler Triple Therapy

Single-inhaler triple therapy (SITT) is strongly preferred over multiple-inhaler combinations because it improves adherence, reduces inhalation technique errors, and simplifies the treatment regimen 1, 2, 6 The Canadian Thoracic Society guidelines acknowledge that some patients may prefer separate inhalers, but SITT remains the recommended approach 1

Safety Considerations and Monitoring

• Pneumonia incidence is slightly higher with ICS-containing regimens, but the benefit-risk ratio favors triple therapy in appropriate patients (number needed to treat = 4 to prevent one moderate-to-severe exacerbation vs number needed to harm = 33 for pneumonia) 2, 6
• Monitor closely for pneumonia in patients who are current smokers, age ≥55 years, have prior exacerbations/pneumonia history, BMI <25 kg/m², or severe airflow limitation 2, 6

Critical Pitfalls to Avoid

• Do not use ICS monotherapy in stable COPD patients at low risk of exacerbations - this is explicitly recommended against 1
• Do not add theophylline to patients already on LAMA/LABA therapy due to low certainty of benefit and high risk of adverse effects and drug interactions 2, 6
• Do not step down from triple therapy during or immediately after an exacerbation, as ICS withdrawal increases recurrent exacerbation risk, particularly in patients with eosinophils ≥300 cells/μL 8
• Do not combine short-acting and long-acting agents of the same class (e.g., do not add ipratropium to a regimen already containing a LAMA like umeclidinium or glycopyrronium) 6